Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis

References

• Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619. doi:10.1016/S0140-6736(12)60150-0
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K; GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi:10.1016/S2468-1253(19)30333-4
   PubMed Web of Science ®Google Scholar
• Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):643–654. doi:10.1016/j.gtc.2020.07.005
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi:10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Curr Med Res Opin. 2019;35(11):1911–1923. doi:10.1080/03007995.2019.1631058
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883. doi:10.14309/ajg.0000000000000183
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725. doi:10.1056/NEJMra1102942
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784. doi:10.1093/ecco-jcc/jjx009
   PubMed Web of Science ®Google Scholar
• Burri E, Maillard MH, Schoepfer AM, et al. Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update. Digestion. 2020;101(Suppl 1):2–15. doi:10.1159/000504092
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–1461. doi:10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Pantavou K, Yiallourou AI, Piovani D, et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: a systematic overview of meta-analyses. United European Gastroenterol J. 2019;7(10):1285–1303. doi:10.1177/2050640619883566
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031–2045.e2011. doi:10.1016/j.cgh.2020.10.039
   PubMed Web of Science ®Google Scholar
• Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8(2):66–82. doi:10.1177/1756283X14558193
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135. doi:10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2(4):151–153. doi:10.1016/j.ijwd.2016.09.003
   PubMedGoogle Scholar
• Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623. doi:10.1111/apt.13083
   PubMed Web of Science ®Google Scholar
• Ehrenberg R, Griffith J, Theigs C, McDonald B. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6):758–765. doi:10.18553/jmcp.2020.19388
   PubMed Web of Science ®Google Scholar
• Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15(9):1302–1307. doi:10.1002/ibd.20924
   PubMed Web of Science ®Google Scholar
• Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol. 2011;4:9–17. doi:10.2147/CEG.S16168
   PubMedGoogle Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50(1):40–53. doi:10.1111/apt.15294
   PubMed Web of Science ®Google Scholar
• Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One. 2020;15(1):e0227914. doi:10.1371/journal.pone.0227914
   PubMed Web of Science ®Google Scholar
• Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–1332. doi:10.1111/apt.12968
   PubMed Web of Science ®Google Scholar
• Baki E, Zwickel P, Zawierucha A, et al. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol. 2015;21(11):3282–3290. doi:10.3748/wjg.v21.i11.3282
   PubMed Web of Science ®Google Scholar
• Bálint A, Farkas K, Palatka K, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohns Colitis. 2016;10(1):26–30. doi:10.1093/ecco-jcc/jjv169
   PubMed Web of Science ®Google Scholar
• Barberio B, Zingone F, D’Incà R, et al. Infliximab originator, infliximab biosimilar, and adalimumab are more effective in Crohn’s disease than ulcerative colitis: a real-life cohort study. Clin Translat Gastroenterol. 2020;11(5):e00177. doi:10.14309/ctg.0000000000000177
   PubMedGoogle Scholar
• Black CM, Yu E, McCann E, Kachroo S. Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data. PLoS One. 2016;11(2):e0149692. doi:10.1371/journal.pone.0149692
   PubMed Web of Science ®Google Scholar
• Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509–1521.e1505. doi:10.1016/j.clinthera.2018.07.013
   PubMed Web of Science ®Google Scholar
• Cesarini M, Katsanos K, Papamichael K, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46(2):135–139. doi:10.1016/j.dld.2013.10.007
   PubMedGoogle Scholar
• Chan W, Lynch N, Bampton P, et al. Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2018;30(7):735–740. doi:10.1097/MEG.0000000000001150
   PubMed Web of Science ®Google Scholar
• Christensen KR, Steenholdt C, Brynskov J. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scand J Gastroenterol. 2015;50(8):1018–1024. doi:10.3109/00365521.2015.1019558
   PubMed Web of Science ®Google Scholar
• Danese S, Panaccione R, Peyrin-Biroulet L, et al. Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension [abstract P448]. J Crohns Colitis. 2020;14(Suppl 1):S403. doi:10.1093/ecco-jcc/jjz203.577
   Google Scholar
• Dignass A, Waller J, Cappelleri JC, et al. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ. 2020;23(4):415–427. doi:10.1080/13696998.2019.1707210
   PubMed Web of Science ®Google Scholar
• Fernández-Salazar L, Barrio J, Muñoz F, et al. Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis. Rev Esp Enferm Dig. 2015;107(9):527–533.
   PubMed Web of Science ®Google Scholar
• Fernández-Salazar L, Muñoz F, Barrio J, et al. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). Scand J Gastroenterol. 2016;51(2):186–195. doi:10.3109/00365521.2015.1070900
   PubMed Web of Science ®Google Scholar
• Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2118–2124. doi:10.1097/MIB.0b013e31829cf401
   PubMed Web of Science ®Google Scholar
• Hiroz P, Vavricka SR, Fournier N, et al. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scand J Gastroenterol. 2014;49(10):1207–1218. doi:10.3109/00365521.2014.946082
   PubMed Web of Science ®Google Scholar
• Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385–1393. doi:10.1093/ecco-jcc/jjaa075
   PubMed Web of Science ®Google Scholar
• Hussey M, Mc Garrigle R, Kennedy U, et al. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2016;28(2):217–221. doi:10.1097/MEG.0000000000000515
   PubMed Web of Science ®Google Scholar
• Iborra M, Pérez-Gisbert J, Bosca-Watts MM, et al. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol. 2017;52(7):788–799. doi:10.1007/s00535-016-1274-1
   PubMed Web of Science ®Google Scholar
• Jung YS, Han M, Park S, Cheon JH. Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study. Dig Dis Sci. 2020;65(5):1436–1444. doi:10.1007/s10620-019-05867-1
   PubMed Web of Science ®Google Scholar
• Kopylov U, Avni-Biron I, Ron Y, et al. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. Dig Liver Dis. 2019;51(1):68–74. doi:10.1016/j.dld.2018.07.040
   PubMedGoogle Scholar
• Lindsay JO, Armuzzi A, Gisbert JP, et al. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017;49(10):1086–1091. doi:10.1016/j.dld.2017.07.010
   PubMedGoogle Scholar
• Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2015;49(8):675–682. doi:10.1097/MCG.0000000000000265
   PubMed Web of Science ®Google Scholar
• McDermott E, Murphy S, Keegan D, O’Donoghue D, Mulcahy H, Doherty G. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis. 2013;7(2):150–153. doi:10.1016/j.crohns.2012.03.016
   PubMed Web of Science ®Google Scholar
• Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–761. doi:10.1016/j.jval.2017.02.005
   PubMed Web of Science ®Google Scholar
• O’Donnell S, Stempak JM, Steinhart AH, Silverberg MS. Higher rates of dose optimisation for infliximab responders in ulcerative colitis than in Crohn’s disease. J Crohns Colitis. 2015;9(10):830–836. doi:10.1093/ecco-jcc/jjv115
   PubMed Web of Science ®Google Scholar
• Olivares D, Alba C, Pérez I, Roales V, Rey E, Taxonera C. Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis. Rev Esp Enferm Dig. 2019;111(11):846–851. doi:10.17235/reed.2019.6148/2018
   PubMed Web of Science ®Google Scholar
• Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020;51(6):637–643. doi:10.1111/apt.15616
   PubMed Web of Science ®Google Scholar
• Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010;105(5):1142–1149. doi:10.1038/ajg.2010.158
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis. 2016;10(9):1015–1023. doi:10.1093/ecco-jcc/jjw067
   PubMed Web of Science ®Google Scholar
• Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS One. 2017;12(4):e0175099. doi:10.1371/journal.pone.0175099
   PubMed Web of Science ®Google Scholar
• Perry C, Fischer K, Elmoursi A, et al. Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis. Dig Dis Sci. 2021;66(6):2051–2058. doi:10.1007/s10620-020-06486-x
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13(16):2328–2332. doi:10.3748/wjg.v13.i16.2328
   PubMed Web of Science ®Google Scholar
• Pöllinger B, Schmidt W, Seiffert A, Imhoff H, Emmert M. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ. 2019;20(2):195–203. doi:10.1007/s10198-017-0953-z
   PubMed Web of Science ®Google Scholar
• Reinglas J, Gonczi L, Verdon C, et al. Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center. Dig Dis Sci. 2020;65(7):2046–2053. doi:10.1007/s10620-019-05982-z
   PubMed Web of Science ®Google Scholar
• Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35(5):562–567. doi:10.1111/j.1365-2036.2011.04986.x
   PubMed Web of Science ®Google Scholar
• Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–1155. doi:10.1111/apt.12727
   PubMed Web of Science ®Google Scholar
• Rubin DT, Dubinsky MC, Panés J, et al. Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: data from OCTAVE open-label, long-term extension study [abstract DOP75]. J Crohns Colitis. 2020;14(Suppl 1):S112–S113. doi:10.1093/ecco-jcc/jjz203.114
   Google Scholar
• Sands BE, Moss AC, Armuzzi A, et al. Efficacy and safety of escalation to tofacitinib 10 mg Bid for patients with UC following loss of response on 5 mg BID maintenance therapy: results from OCTAVE open-label, long-term extension study [abstract DOP73]. J Crohns Colitis. 2020;14(Suppl 1):S110–S111. doi:10.1093/ecco-jcc/jjz203.112
   PubMedGoogle Scholar
• Stefanovic S, Detrez I, Compernolle G, et al. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol. 2021;33(1):54–61. doi:10.1097/MEG.0000000000001843
   PubMed Web of Science ®Google Scholar
• Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340–348. doi:10.1111/j.1365-2036.2010.04531.x
   PubMed Web of Science ®Google Scholar
• Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol. 2014;20(27):9170–9177. doi:10.3748/wjg.v20.i27.9170
   PubMed Web of Science ®Google Scholar
• Taxonera C, Barreiro-de Acosta M, Calvo M, et al. Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis. Dig Dis Sci. 2015;60(10):3075–3084. doi:10.1007/s10620-015-3735-4
   PubMed Web of Science ®Google Scholar
• Taxonera C, Iglesias E, Muñoz F, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci. 2017;62(2):481–490. doi:10.1007/s10620-016-4398-5
   PubMed Web of Science ®Google Scholar
• Taxonera C, Rodríguez C, Bertoletti F, et al. Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2017;23(8):1394–1402. doi:10.1097/MIB.0000000000001144
   PubMed Web of Science ®Google Scholar
• Taxonera C, Iborra M, Bosca-Watts MM, et al. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin. 2019;35(7):1297–1304. doi:10.1080/03007995.2019.1579557
   PubMed Web of Science ®Google Scholar
• Torres P, Cañete F, Núñez L, et al. Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease? Dig Dis Sci. 2020;65(7):2036–2043. doi:10.1007/s10620-019-06010-w
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Picchio M, et al. Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first “real-life” experience in primary gastroenterology centers in Italy. Ann Gastroenterol. 2014;27(4):369–373.
   PubMedGoogle Scholar
• Tursi A, Elisei W, Faggiani R, et al. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: a real-life multicenter, observational study in primary inflammatory bowel disease centers. Medicine. 2018;97(34):e11897. doi:10.1097/MD.0000000000011897
   PubMed Web of Science ®Google Scholar
• Viola A, Pugliese D, Renna S, et al. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: a multicenter retrospective study. Dig Liver Dis. 2019;51(4):510–515. doi:10.1016/j.dld.2018.10.013
   PubMedGoogle Scholar
• Wang Y, Wang J, Pekow J, et al. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019;34(12):2090–2095. doi:10.1111/jgh.14751
   PubMed Web of Science ®Google Scholar
• Yamada S, Yoshino T, Matsuura M, et al. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol. 2014;14:80. doi:10.1186/1471-230X-14-80
   PubMed Web of Science ®Google Scholar
• Yamamoto-Furusho JK, Al Harbi O, Armuzzi A, et al. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: the EXPLORE study. Dig Liver Dis. 2020;52(8):869–877. doi:10.1016/j.dld.2020.05.031
   PubMedGoogle Scholar
• Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Market Access Health Policy. 2017;5(1):1272308. doi:10.1080/20016689.2016.1272308
   PubMedGoogle Scholar
• Bhat S, Limdi JK, Cross RK, Farraye FA. does similarity breed contempt? A review of the use of biosimilars in inflammatory bowel disease. Dig Dis Sci. 2021;66(8):2513–2532. doi:10.1007/s10620-021-07114-y
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14(1):22–31. doi:10.1038/nrgastro.2016.155
   PubMed Web of Science ®Google Scholar
• Park SH, Park JC, Lukas M, Kolar M, Loftus EV. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res. 2020;18(1):34–44. doi:10.5217/ir.2019.09147
   PubMed Web of Science ®Google Scholar
• San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/jamanetworkopen.2019.17379
   PubMed Web of Science ®Google Scholar